We have recently read with interest the article by Kaya et al 1 in CHEST (August 2012) reporting on a patient suffering from chronic eosinophilic pneumonia (CEP) who responded successfully to omalizumab. Five years ago, we attended a 43-year-old nonsmoking man who complained of cough, fever, dyspnea, and wheezing. On the basis of his clinical presentation, peripheral blood and BAL eosinophilia, and the presence of bilateral peripheral infi ltrates on the chest radiograph, the diagnosis of CEP was made. As in the Kaya et al 1 case, oral corticosteroids (OCs) were started with an initial successful response. After 3 months of therapy, the dose of OCs was progressively tapered. When the dose reached 10 mg prednisolone, a relapse occurred that forced us to increase the dose of OCs. The patient improved, and bronchospasm and chest infi ltrates disappeared.
Can Omalizumab Be Effective in Chronic Eosinophilic Pneumonia ?
To the Editor:
We have recently read with interest the article by Kaya et al 1 in CHEST (August 2012) reporting on a patient suffering from chronic eosinophilic pneumonia (CEP) who responded successfully to omalizumab. Five years ago, we attended a 43-year-old nonsmoking man who complained of cough, fever, dyspnea, and wheezing. On the basis of his clinical presentation, peripheral blood and BAL eosinophilia, and the presence of bilateral peripheral infi ltrates on the chest radiograph, the diagnosis of CEP was made. As in the Kaya et al 1 case, oral corticosteroids (OCs) were started with an initial successful response. After 3 months of therapy, the dose of OCs was progressively tapered. When the dose reached 10 mg prednisolone, a relapse occurred that forced us to increase the dose of OCs. The patient improved, and bronchospasm and chest infi ltrates disappeared.
During the process of OC tapering, a new relapse occurred, bronchospasm being the most relevant clinical symptom that forced us to increase again the dose of OCs. A skin prick test was performed that was positive for mite dust. Total blood IgE level was 253 IU/mL. Omalizumab treatment was started at the dose calculated according to the patient's weight and IgE concentration. The patient progressively improved, and after 18 months of treatment (6 months to check clinical response followed by 12 months of stabilization), according to our decreasing-dose protocol of omalizumab, 2 the dose of omalizumab was progressively tapered by 50% every 6 months. The patient's tolerance was excellent, and omalizumab treatment could be safely quit 12 months later. The patient has remained free of symptoms of CEP for . 2 years, requiring only two short courses of OCs for his asthma.
The IgE-dependent infl ammatory phenomena have been studied in depth and are clearly recognized in atopic subjects, and the anti-IgE blocking effect of omalizumab has been clearly shown. Additional benefi ts can be provided by the fi ndings of Kalesnikoff et al, 3 who observed that by binding to its high-affi nity receptor, Fc ´ RI, IgE was able to induce intracellular signaling pathways, resulting in the production of cytokines and the enhancement of mast-cell survival on its own, without cross-linking by allergens. In addition, IgE can directly bind and activate receptors present on eosinophils, neutrophils, and monocytes. As a result, the rationale for the use of omalizumab in diseases other than allergy is based on its blocking effect on IgE, which inhibits part of the T helper cell type 2 immune response, thus, reducing recruitment and activation of effector cells of the infl ammatory process, including eosinophils. Because IgE effector cells (ie, mast cells and basophils) are a source of proinfl ammatory molecules, anti-IgE therapy may have antiinfl ammatory properties that reduce circulating and tissue eosinophils 4 ; indeed, this role has been suggested in other diseases, such as eosinophil-associated GI disorders. 5 More recently, Noga et al 4 demonstrated an increase in eosino phil apoptosis and a decrease in granulocyte-macrophage colony-stimulating factor. All this information can help to explain the benefi ts of omalizumab in CEP.
In their report, Kaya et al 1 communicate that their patient remains free of symptoms 15 months after omalizumab treatment began, but they do not state future treatment options. We believe some of these patients can benefi t from a decreasing dose protocol. 2 
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We read the correspondence by Drs Domingo and Pomares about our case report 1 with interest. The case described by the authors, and probably some other unpublished cases, support the potential benefi ts of omalizumab in chronic eosinophilic pneumonia and other hypereosinophilic states.
The mechanism of the effect of omalizumab on hypereosinophilia is unclear; however, the defective expression of CD23 on B cells, as in our case, might be an explanation. 1 The low-affi nity receptor for IgE, Fc RII, also known as CD23, is expressed on In an issue of CHEST (September 2012), Nanchal et al 1 presented interesting data about the existence of a "weekend effect" for pulmonary embolism. Patients admitted to the hospital on a weekend, in fact, had a 19% increased risk of death. These results represent further confi rmation of previous reports from Canada (cited by the authors) and from the Emilia-Romagna region of Italy by our group 2 that both found a 17% increased risk of death.
We have extensively explored the possible presence of a different mortality rate between weekdays and weekends and confi rmed an even greater increased risk of death for other acute cardiovascular diseases as well (ie, acute heart failure [OR, 1.33] 3 and aortic aneurysm rupture or dissection [OR, 1.31] 4 ). Medical and nursing understaffi ng, shortage of diagnostic or procedural services, and presence of inexperienced residents have been suggested as possible causes. However, the data collected in Italy (and in the Emilia-Romagna region in particular) do not support such interpretations, since that health system and the hospital service organization in Italy are not comparable with that of countries like the United States or the United Kingdom. 4 Temporal aspects of onset of acute cardiovascular and cerebrovascular diseases might play a role as well, and patterns of circadian and seasonal times of onset of certain diseases are known. It is possible that acute diseases do not present with equal severity relative to time, that is, day of the week or hour of the day. A single-center study on acute coronary syndromes (ACSs) explored this possibility and showed that, although there were fewer ACS admissions than expected on nights and weekends, the proportion of patients with ACS presenting with ST-elevation myocardial infarctions was 64% higher on weekends. 5 A higher severity might be linked with higher risk of mortality, and several parameters of severity collected by Nanchal et al 1 3 In addition, CD23 serves as a negative regulator of IgE production, which has been demonstrated through experimental animal studies in vivo. Increased production of IgE and defective antigen presentation were found in mice defi cient in CD23. 4 Accordingly, our case has defective expression of CD23 on B cells. Because of technical and fi nancial reasons, we could analyze neither mutation of this molecule nor its soluble fragment in serum. We suggest that future studies investigating the role of CD23 (both its soluble fragments and expression on infl ammatory cells, including B cells and eosinophils) and its mutation may provide some information about allergic and hypereosinophilic disorders and the mechanism of action of omalizumab on them.
The optimal duration of omalizumab treatment in allergic diseases is not known. It has been reported that lowering the recommended omalizumab dose may likely result in a clinical deterioration. 5 On the other hand, however, after the discontinuation of the drug some effect of the therapy may continue up to 3 years. 6 In our chronic eosinophilic pneumonia case, we plan to taper and discontinue omalizumab after completing at least 3 years of therapy .
